Publications & Works

Publication Network
Articles 62
All (62)
SCI-E, SSCI, AHCI (48)
SCI-E, SSCI, AHCI, ESCI (55)
ESCI (7)
Scopus (57)
TRDizin (15)
Other Publications (3)

1. Extra intestinal manifestations may increase the risk of synchronous and metachronous development of other extraintestinal manifestations in patients with Crohn’s disease

Ozkahraman A., Kayar Y., Dertli R., Konur S., Kılıc G., Baran B., et al.
Scientific Reports , vol.15, no.1, 2025 (SCI-Expanded) identifier

2. A prospective study on the role of non-invasive tests in the evaluation of diabetes mellitus associated steatotic liver disease

İstemihan Z., Bektaş F., Bardak A. E., Kızıltaş C., Kemeç G., İmanov Z., et al.
Scientific Reports , vol.15, no.1, 2025 (SCI-Expanded) identifier identifier identifier

3. Maternal and Fetal Outcomes of Pregnancies in Wilson’s Disease: A Single-Centre Real-Life Experience

Demir K., Çifcibaşı Örmeci A., Çavuş B., İstemihan Z., Genç Uluçeçen S., Atasoy A., et al.
Turkish Journal of Gastroenterology , vol.36, 2025 (Scopus, TRDizin)

4. USTEKINUMAB EFFECTIVENESS AND SUSTAINABILITY IN ULCERATIVE COLITIS AND CROHN’S DISEASE

İstemihan Z., Teberik Kama E., Altın S., İmanov Z., Şenkal İ. V., Nurıyev K., et al.
Journal of İstanbul Faculty of Medicine , no.88, pp.256-263, 2025 (Peer-Reviewed Journal)

5. Anxiety and Depression Outcomes in Liver Transplant Candidates and Recipients Using the Hospital Anxiety and Depression Scale

Bardak A. E., Cifcibasi Ormeci A., Yildiz Z., Senkal V., Imanov Z., Istemihan Z., et al.
Transplantation Proceedings , vol.57, no.6, pp.1170-1175, 2025 (SCI-Expanded) Sustainable Development identifier identifier

6. The role of GALAD score in the surveillance of hepatocellular carcinoma.

İstemihan Z., Şenkal İ. V., Karaca D., Nurıyev K., Rustamzade A., Genç Uluçeçen S., et al.
Scientific reports , vol.15, no.1, pp.22279, 2025 (SCI-Expanded) identifier identifier

7. The Role of Pancreatic Enzyme Insufficiency in the Etiology of Functional Dyspepsia Resistant to Standard Treatment

kemik f., CEYLAN G., Aydın A. F., Çavuş B., Ormeci A., Imanov Z., et al.
Turkish Journal of Gastroenterology , vol.36, no.7, pp.467-473, 2025 (SCI-Expanded) identifier identifier identifier identifier

8. “Liver-Related Mortality in Type 2 Diabetes: Important Insights and Methodological Considerations”

Gurbanov A., Genç Uluçeçen S., Çifçibaşi Örmeci A.
Liver International , vol.45, no.6, 2025 (SCI-Expanded) identifier identifier

9. Encapsulating Peritoneal Sclerosis: The Consequence of Recurrent Spontaneous Bacterial Peritonitis

Bardak A. E., Selvi B., Poyanlı A., Çifçibaşı Örmeci A.
Digestive Diseases and Sciences , vol.70, no.2, pp.443-444, 2025 (SCI-Expanded) identifier identifier

10. Lumen-apposing metal stents for pancreatic fluid collections: has advancing technology encouraged over-reach?

Ağargün B. F., Cavus B., Cifcibasi Ormeci A., Demir K.
Gut , 2025 (SCI-Expanded) identifier identifier

11. Virological and Biochemical Effects of Tenofovir Alafenamide in Different Patient Groups With Chronic Hepatitis B Virus Infection in Real-World Cohort

Bektas E., Yilmaz A., Kikili C. I., Nuriyev K., Istemihan Z., Senkal I. V., et al.
International Journal of Hepatology , vol.2025, no.1, 2025 (ESCI) identifier

12. What are the predictors of malignancy in inflammatory bowel disease?

İstemihan Z., Çavuş B., Bardak A. E., Kirkoğlu A. M., Kiziltaş C., Silay R., et al.
Turkish Journal of Medical Sciences , vol.55, no.4, pp.846-854, 2025 (SCI-Expanded) identifier identifier identifier

13. Decisional Control Preferences in Managing Intraductal Papillary Mucinous Neoplasms of the Pancreas

Ağargün B. F., Dağcı G., Çavuş B., Çifcibaşı Örmeci A.
Pancreas , 2025 (SCI-Expanded) identifier

14. Aceruloplasminemia as a rare hereditary disease: four case reports in a single center

İstemihan Z., İmanov Z., Çavuş B., Çifcibaşı Örmeci A., Akyüz F., Beşışık S. F., et al.
Baylor University Medical Center Proceedings , no.0, pp.1-4, 2024 (Scopus)

15. Changing Trends in the Etiology of Cirrhosis in Türkiye: A Multicenter Nationwide Study

Üçbilek E., Yıldırım A. E., Ellik Z., Turan İ., Haktanıyan B., Orucu B., et al.
Turkish Journal of Gastroenterology , vol.35, no.10, pp.772-777, 2024 (SCI-Expanded) Sustainable Development identifier

16. Is the Y90-radioembolization treatment effective on the intermediate-advanced stage of hepatocellular carcinoma and what is the albumin-bilirubin score’s prediction factor for survival?

Evirgen S., ÇAVUŞ B., Gokturk S., Iliaz R., ÖZKAN Z. G., Baran B., et al.
Hepatology Forum , vol.4, no.3, pp.103-107, 2023 (Scopus) Creative Commons License Sustainable Development identifier

17. Two Cases of Malignant Transformation in Crohn’s Disease with Perianal Involvement

DAĞCI G., VARELCİ S., BÜYÜK M., ÇAVUŞ B., ÇİFCİBAŞI ÖRMECİ A., AKYÜZ F., et al.
Kare Publishing , vol.2, 2023 (Peer-Reviewed Journal)

18. Different Faces of Eosinophilic Infiltration of Gastrointestinal System

İSTEMİHAN Z., ÇAVUŞ B., BERKER N., Nuriyev K., Şenkal V., İmanov Z., et al.
Journal of Enterocolitis , vol.1, no.3, pp.68-71, 2022 (Peer-Reviewed Journal)

19. Mucocutaneous Manifestations and Associated Factors in Patients with Crohn's Disease

Kayar Y., Dertli R., Konür Ş., Ağın M., Al Kafee A., Baran B., et al.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology , vol.33, no.11, pp.945-954, 2022 (SCI-Expanded) identifier identifier

20. What is the effect of subepithelial lesions of the esophagus on esophageal motility?

Oermeci A., Cavus B., Akas R., Istemihan Z., Imanov Z., Senkal V., et al.
European review for medical and pharmacological sciences , vol.26, no.17, pp.6300-6309, 2022 (SCI-Expanded) Sustainable Development identifier identifier identifier

21. Is anterior segment OCT superior to slit-lamp biomicroscopic examination for Kayser Flesicher ring in Wilson's disease?

Ormeci A., Bayraktar S., Isik A. O., Cavus B., Akas R., Istemihan Z., et al.
European review for medical and pharmacological sciences , vol.26, no.14, pp.5178-5185, 2022 (SCI-Expanded) identifier identifier identifier

22. Cyclosporine Therapy as a Rescue Treatment in Steroid Refractory Acute Severe Ulcerative Colitis: A Real Life Data From a Tertiary Center

Evirgen S., Iliaz R., Akyuz F., Cavus B., Gokturk S., Ormeci A., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , vol.33, no.6, pp.463-469, 2022 (SCI-Expanded) identifier identifier identifier identifier

23. Are Hepatobiliary Manifestations Related to the Site of Involvement in Inflammatory Bowel Disease?

İstemihan Z., Çifcibaşı Örmeci A., Çavuş B., Şenkal İ. V., İmanov Z., Nuriyev K., et al.
Journal of Enterocolitis , vol.1, pp.12-16, 2022 (Peer-Reviewed Journal)

24. EVALUATION OF HELICOBACTER PYLORI FREQUENCY AND GASTRIC ANTRUM PATHOLOGY FINDINGS IN PATIENTS WITH PORTAL HYPERTENSION

Cavus B., Ormeci A., Evirgen S., Iliaz R., Atasoy A., Yegen G., et al.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI , vol.85, no.2, pp.211-215, 2022 (ESCI) Creative Commons License identifier identifier

25. Can Interferon Therapy Change the Natural Course of Hepatitis Delta Infection?: a Clinical and Pathological Study

BAKKALOĞLU O. K., Yildirim O., Cavus B., Evirgen S., Gokturk S., Ormeci A., et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , vol.66, no.1, 2022 (SCI-Expanded) Sustainable Development identifier identifier identifier

26. A mysterious cause of recurrent acute liver dysfunction for over a decade

Dirim A. B., Kalayci T., Guzel Dirim M., Demir S., Cavus B., Cifcibasi Ormeci A., et al.
GASTROENTEROLOGY REPORT , vol.10, 2022 (SCI-Expanded) identifier identifier identifier

27. The Relationship between Ocular Vascular Changes and the Levels of Malondialdehyde and Vascular Endothelial Growth Factor in Patients with Inflammatory Bowel Disease

Sengul S., Poturoglu S., Samanci C., Ustabasioglu F., Koldas M., Duman A., et al.
OCULAR IMMUNOLOGY AND INFLAMMATION , vol.29, no.7-8, pp.1459-1463, 2021 (SCI-Expanded) identifier identifier identifier

28. Etiology of Cirrhosis in Turkey: A National Cohort Study

YILDIRIM A. E., ÜÇBİLEK E., Oruncu M. B., TURAN İ., DEMİR M., Koksal A., et al.
JOURNAL OF HEPATOLOGY , vol.75, 2021 (SCI-Expanded) identifier

29. ANALYSIS OF GENOTYPE, SUBGENOTYPE AND SEROTYPE OF OCCULT HEPATITIS B VIRUS

Cakal B., Atasoy A., Cavus B., Ormeci A., Poda M., Bulakci M., et al.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI , vol.84, no.3, pp.402-410, 2021 (ESCI) Sustainable Development identifier identifier

30. The development of extraintestinal manifestation and related risk factors in Crohn's patients

Kayar Y., Dertli R., Konur S., Agin M., Baran B., Ormeci A., et al.
IRISH JOURNAL OF MEDICAL SCIENCE , vol.190, no.2, pp.597-604, 2021 (SCI-Expanded) identifier identifier identifier

31. What are the predictors for recurrence of Crohn's disease after surgery?

Ozgur İ., Kulle C. B., Buyuk M., Ormeci A., Akyuz F., Balik E., et al.
MEDICINE , vol.100, no.14, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

32. Prolonged Severe Watery Diarrhea in a Long-Term Myeloma Survivor: An Unforeseen Infection with Cystoisospora belli

Tiryaki T. O., Anıl K. U., Büyük M., Yıldırım A. Y., Atasoy A., Çiftçibaşı Örmeci A., et al.
TURKISH JOURNAL OF HEMATOLOGY , vol.38, no.2, pp.171-173, 2021 (SCI-Expanded, Scopus, TRDizin) Sustainable Development identifier identifier identifier identifier

33. IMPLICATION OF SERUM IL-17 LEVELS IN CHRONIC HEPATITIS B PATIENTS

ÇAKAL B., ÇAVUŞ B., Atasoy A., Ormeci A., BULAKÇI M., GÜLLÜOĞLU M., et al.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI , vol.84, no.1, pp.68-75, 2021 (ESCI) Creative Commons License identifier identifier

34. Myeloma and Cystoisospora belli REPLY

Tiryaki T. O., Anil K. U., Buyuk M., Yildirim A. Y., Atasoy A., Ormeci A., et al.
TURKISH JOURNAL OF HEMATOLOGY , vol.38, no.3, pp.230, 2021 (SCI-Expanded) identifier

35. The effect of liver test abnormalities on the prognosis of COVID-19.

Medetalibeyoglu A., Catma Y., Senkal N., Ormeci A., Cavus B., Kose M., et al.
Annals of hepatology , vol.19, no.6, pp.614-621, 2020 (SCI-Expanded, Scopus) Sustainable Development identifier identifier identifier

36. Efficacy of adalimumab in mild-to-moderate inflammatory bowel disease: Real-life data from single-centre experience in the long-term period

Akyuz F., Ormeci A., Namazova N., Guzel M., Abbasgoulizadeh A., Tahincioglu L., et al.
JOURNAL OF CROHNS & COLITIS , 2020 (SCI-Expanded) identifier

37. Gastroesophageal Reflux in Asymptomatic Patients with Diabetes: An Impedance Study Diabetes, Obesity and Gastroesophageal Reflux

Gokturk S., Akyuz F., Arici S., Alpaslan B., Ormeci A., Soyer O. M., et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES , vol.128, no.1, pp.52-58, 2020 (SCI-Expanded, Scopus) Sustainable Development identifier identifier identifier

38. Risk factors associated with progression to intestinal complications of Crohn disease

Kayar Y., Baran B., Ormeci A., Akyuz F., Demir K., Besisik F., et al.
CHINESE MEDICAL JOURNAL , vol.132, no.20, pp.2423-2429, 2019 (SCI-Expanded) identifier identifier identifier

39. Usage of HCV viremic organs in liver transplantation to anti-HCV negative recipients: The current status and review of literature

ÇİFCİBAŞI ÖRMECİ A., Yildiz C., Seberi B., Gurakar M., Simsek C., Gurakar A.
TURKISH JOURNAL OF GASTROENTEROLOGY , vol.30, no.9, pp.771-775, 2019 (SCI-Expanded) Sustainable Development identifier

40. Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?

Akyuz F., Cavus B., Iliaz R., Soyer O. M., Ormeci A., Evirgen S., et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , vol.31, no.7, pp.777-780, 2019 (SCI-Expanded) Sustainable Development identifier identifier identifier

41. Does the number of mucosal immune cells differ in irritable bowel syndrome and its subtypes?

İLIAZ R., AKYÜZ F., Yeğen G., ÖRMECI A., GÖKTÜRK S., AKYÜZ Ü., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , vol.29, no.4, pp.384-391, 2018 (SCI-Expanded) identifier identifier identifier

42. Current state and clinical outcome in Turkish patients with hepatocellular carcinoma

Ekinci O., Baran B., Ormeci A., Soyer O. M., Gokturk S., Evirgen S., et al.
WORLD JOURNAL OF HEPATOLOGY , vol.10, no.1, pp.51-61, 2018 (ESCI) identifier identifier identifier

43. Role of biochemistry and cytological analysis of cyst fluid for the differential diagnosis of pancreatic cysts A retrospective cohort study

Soyer O. M., Baran B., Ormeci A., Sahin D., Gokturk S., Evirgen S., et al.
MEDICINE , vol.96, no.1, 2017 (SCI-Expanded) identifier identifier identifier

44. A rare congenital liver anomaly: Hypoplasia of left hepatic lobe

Ormeci T., Erdogan S. T., ÇİFCİBAŞI ÖRMECİ A., Aygun C.
JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION , vol.66, no.12, pp.1662-1664, 2016 (SCI-Expanded) identifier

45. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels

Ormeci A., Aydın Y., Sumnu A., Baran B., Soyer O. M., Pinarbasi B., et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES , vol.52, pp.68-73, 2016 (SCI-Expanded) Sustainable Development identifier identifier identifier

46. Retention during capsule endoscopy: Is it a real problem in routine practice?

Ormeci A., Akyuz F., Baran B., Gokturk S., Ormeci T., Pinarbasi B., et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH , vol.44, no.4, pp.968-975, 2016 (SCI-Expanded) identifier identifier identifier

47. Comparison of the efficacy of 12 months and longer courses of interferon therapy for the treatment of chronic delta hepatitis: a retrospective cohort study

Soyer O. M., Baran B., Ormeci A., Gokturk S., Aydin E., Onel D., et al.
POSTGRADUATE MEDICINE , vol.128, no.4, pp.432-438, 2016 (SCI-Expanded) Sustainable Development identifier identifier identifier

48. Can Helicobacter pylori be eradicated with high-dose proton pump inhibitor in extensive metabolizers with the CYP2C19 genotypic polymorphism?

ORMECI A., Emrence Z., BARAN B., SOYER O., GOKTURK S., EVIRGEN S., et al.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES , vol.20, no.9, pp.1795-1797, 2016 (SCI-Expanded) identifier identifier identifier

49. What is the impact of capsule endoscopy in the long term period?

Ormeci A., Akyuz F., Baran B., Gokturk S., Ormeci T., Pinarbasi B., et al.
WORLD JOURNAL OF GASTROINTESTINAL ENDOSCOPY , vol.8, no.7, pp.344-348, 2016 (ESCI) identifier identifier

50. Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole

Ormeci A., Emrence Z., Baran B., Gokturk S., Soyer O. M., Evirgen S., et al.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES , vol.20, no.5, pp.879-885, 2016 (SCI-Expanded) identifier identifier identifier

51. Steroid-refractory inflammatory bowel disease is a risk factor for CMV infection

Ormeci A., Akyuz F., BARAN B., SOYER O., GÖKTÜRK S., ONEL M., et al.
European Review for Medical and Pharmacological Sciences , vol.20, no.5, pp.858-865, 2016 (SCI-Expanded) identifier identifier identifier

52. Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus

Baran B., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., Akyuz F., et al.
LIVER INTERNATIONAL , vol.35, no.10, pp.2265-2274, 2015 (SCI-Expanded) Sustainable Development identifier identifier identifier

53. Small bowel mucosal damage in familial Mediterranean fever: results of capsule endoscopy screening

Demir A., Akyuz F., Gokturk S., Evirgen S., Akyuz U., Ormeci A., et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY , vol.49, no.12, pp.1414-1418, 2014 (SCI-Expanded) identifier identifier identifier

54. Effects of Polymorphisms in Interferon lambda 3 (Interleukin 28B) on Sustained Virologic Response to Therapy in Patients With Chronic Hepatitis D Virus Infection

Yilmaz E., Baran B., Soyer O. M., Onel M., Onel D., Ormeci A., et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY , vol.12, no.10, pp.1753-1758, 2014 (SCI-Expanded) Sustainable Development identifier identifier identifier

55. Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma

Karabulut S., Tas F., Akyuz F., Ormeci A., Serilmez M., Soydinc H. O., et al.
TUMOR BIOLOGY , vol.35, no.3, pp.2327-2333, 2014 (SCI-Expanded, Scopus) Sustainable Development identifier identifier identifier

56. Treatment failure may lead to accelerated fibrosis progression in patients with chronic hepatitis C

Baran B., Gulluoglu M., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., et al.
JOURNAL OF VIRAL HEPATITIS , vol.21, no.2, pp.111-120, 2014 (SCI-Expanded) Sustainable Development identifier identifier identifier

57. Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B

KESKİN O., Ormeci A., Baran B., Kabacam G., Tuzun A., Karatayli E., et al.
ANTIVIRAL THERAPY , vol.19, no.6, pp.543-550, 2014 (SCI-Expanded) Sustainable Development identifier identifier identifier

58. Effect of Genotypic Differences in CYP2C19 and on Cure Rates for Helicobacter pylori Infection by Triple Therapy With Different Proton Pump Inhibitors

Demir K., ORMECI A., Emrence Z., Gokturk S., Baran B., SOYER O. M., et al.
GASTROENTEROLOGY , vol.144, no.5, 2013 (SCI-Expanded) identifier

59. Efficacy of Tenofovir in Patients with Lamivudine Failure Is Not Different from That in Nucleoside/Nucleotide Analogue-Naive Patients with Chronic Hepatitis B

Baran B., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., Bozbey H. U., et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY , vol.57, no.4, pp.1790-1796, 2013 (SCI-Expanded) Sustainable Development identifier identifier identifier

60. Efficacy of pegylated interferon-alpha treatment for 24 months in chronic delta hepatitis and predictors of response

Karaca C., Soyer O. M., Baran B., Ormeci A., Gokturk S., Aydin E., et al.
ANTIVIRAL THERAPY , vol.18, no.4, pp.561-566, 2013 (SCI-Expanded) identifier identifier identifier

61. Treatment of aortic valve stenosis and gastrointestinal bleeding by transcatheter aortic valve implantation in Heyde syndrome

Gul M., Surgit O., Ozal E., Ormeci A., Bakir I.
ANADOLU KARDIYOLOJI DERGISI-THE ANATOLIAN JOURNAL OF CARDIOLOGY , vol.12, no.8, pp.691-693, 2012 (SCI-Expanded) identifier identifier identifier

62. A rare complication of interferon treatment: optic neuropathy

Gokturk S., Atay K., ÇİFCİBAŞI ÖRMECİ A., Baran B., Soyer O. M., AKYÜZ F., et al.
ANNALS OF GASTROENTEROLOGY , vol.24, no.4, pp.335, 2011 (ESCI) identifier identifier
Papers Presented at Peer-Reviewed Scientific Conferences 34

1. Steatotic liver disease in diabetic patients: more serious diabetes mellitus, more serious liver disease

İstemihan Z., Bektaş F., Bardak A. E., Kızıltaş C., Kemeç G., Nurıyev K., et al.
EASL Congress 2024, Milan, Italy, 5 - 08 June 2024, pp.551, (Summary Text)

2. The relationship between spleen stiffness and portal hypertension liver transplant patients

Nurıyev K., İstemihan Z., Telli P., Qurbanov A., Yağlı M. A., Dağcı G., et al.
EASL Congress 2024, Milan, Italy, 5 - 08 June 2024, pp.377-378, (Summary Text)

3. 10-year results under tenofovir disoproxil fumarate and entecavir in chronic hepatitis B; HBV clearance rare, disease outcomes good

İstemihan Z., Kemeç G., Cebeci T., Çetin O., Genç Uluçeçen S., Rüstemzade A., et al.
EASL Congress 2024, Milan, Italy, 5 - 08 June 2024, pp.803, (Summary Text)

4. Clinical characteristics of patients with hereditary hemorrhagic telangiectasia: Real-life data, single-center experience

İstemihan Z., Bardak A. E., Nurıyev K., Rüstemzade A., Genç Uluçeçen S., Çavuş B., et al.
ESGE Days 2024, Berlin, Germany, 25 - 27 April 2024, pp.297, (Summary Text)

5. Wilson Hastalığında Aile İçi Genetik Taramanın Kliniğe Önemli Katkıları

Şahin A., ÇİFCİBAŞI ÖRMECİ A., SUER İ., DEMİR K., KALAYCI T., ÇEFLE K., et al.
40. Ulusal Gastroenteroloji Haftası ve 11. Gastroenteroloji Cerrahisi Kongresi, Antalya, Turkey, 21 - 26 November 2023, (Summary Text)

6. Otoimmün Tanılı Hastalarda Viral Serolojik Profilin Değerlendirilmesi

Küçükkaya S., Çaklovica Küçükkaya İ., Çavuş B., Safran N., Önel M., Kırkoyun Uysal H., et al.
7. Ulusak Klinik Mikrobiyoloji Kongresi (KLİMUD), Muğla, Turkey, 1 - 05 November 2023, pp.635, (Summary Text)

7. ARE THERE NEW PRACTICAL MARKERS TO PREDICT MALIGNANCY IN PANCREATIC CYST FLUIDS?

Anıl K. U., Çavuş B., Çifcibaşı Örmeci A., İmanov Z., Şenkal İ. V., Nurıyev K., et al.
Digestive Disease Week 2023, Washington, United States Of America, 6 - 09 May 2023, pp.774, (Summary Text)

8. Real-world data of tenofovir alafenamide in treatment-naive and experienced patients with Chronic Hepatitis B: more efficacy, less side effects

Bektaş E., Yılmaz A., Kıkılı C. İ., Nurıyev K., İstemihan Z., Şenkal İ. V., et al.
39. Ulusal Gastroenteroloji Haftası ve 10. Gastroenteroloji Cerrahisi Kongresi, Antalya, Turkey, 22 - 27 November 2022, pp.1159-1162, (Summary Text)

9. A RARE CAUSE OF HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: VISCERAL LEISHMANIASIS

Yılmaz A., Bektaş E., Bilgin E., Şenkal İ. V., Çavuş B., Çifcibaşı Örmeci A., et al.
24. Ulusal İç Hastalıkları Kongresi, Antalya, Turkey, 19 - 23 October 2022, pp.118-119, (Full Text) Sustainable Development

10. A CASE OF EXTRAPULMONARY SARCOIDOSIS WITH HYPERLIPIDAEMIA DUE TO GRANULOMATOUS HEPATITIS AND INTRAHEPATIC CHOLESTASIS

Bektaş E., Yılmaz A., Bilgin E., Mutlu Ü., Çavuş B., Çifcibaşı Örmeci A., et al.
24. Ulusal İç Hastalıkları Kongresi, Antalya, Turkey, 19 - 23 October 2022, pp.136-137, (Full Text)

11. REAL-WORLD DATA OF TENOFOVIR ALAFENAMIDE IN TREATMENT-NAIVE AND EXPERIENCED PATIENTS WITH CHRONIC HEPATITIS B: MORE EFFICACY, LESS SIDE EFFECTS

Bektaş E., Yılmaz A., Kıkılı C. İ., Nurıyev K., İstemihan Z., Şenkal İ. V., et al.
AASLD Liver Meeting , District Of Columbia, United States Of America, 4 - 08 November 2022, vol.76, pp.299, (Summary Text)

12. Dekompanse karaciğer sirozunda ince barsak tutulumlu diffüz büyük b hücreli lenfoma olgusu

Teberik Kama E., İstemihan Z., Çifcibaşı Örmeci A., Akyüz F., Kaymakoğlu S.
24. Ulusal İç Hastalıkları Kongresi, Antalya, Turkey, 19 - 23 October 2022, pp.140, (Summary Text)

13. İshal ve kilo kaybının nadir bir nedeni:Amiloidoz

Çiftçi A. C., Konyaoğlu H., Şenkal İ. V., Çavuş B., Çifcibaşı Örmeci A., Akyüz F., et al.
21. Çapa Gastroenteroloji Günleri, İstanbul, Turkey, 31 March - 02 April 2022, pp.70, (Full Text)

14. Budd-Chiari Sendromu’nda Hepatoselüler Kanser ve Mortalitenin Değerlendirilmesi

İstemihan Z., Nurıyev K., Şenkal İ. V., İmanov Z., Sarıdal M. K., Akas R., et al.
38. Ulusal Gastroenteroloji Haftası, 9. Gastroenteroloji Cerrahisi Kongresi, Antalya, Turkey, 16 - 21 November 2021, pp.219, (Summary Text) Sustainable Development

15. Ön Segment Optik Koherans Tomografi (OCT), Wilson hastalığı tanısında Kayser Fleischer Halkası varlığını değerlendirmeki yeri - Ehil oftalmolog gerekliliğine son verecek mi?

Çifcibaşı Örmeci A., Bayraktar Ş., Işık A. O., İstemihan Z., Sarıdal M. K., Akas R., et al.
38. Ulusal Gastroenteroloji Haftası, 9. Gastroenteroloji Cerrahisi Kongresi, Antalya, Turkey, 16 - 21 November 2021, pp.218, (Summary Text)

16. Girişimsel Gastroenterolojik İşlemlerde Hastaların Doktor Tercihinde Cinsiyet Önemli mi?

Kara İnci A., Zaralı S., Akyüz M., İmanov Z., Şenkal İ. V., İstemihan Z., et al.
38. Ulusal Gastroenteroloji Haftası, 9. Gastroenteroloji Cerrahisi Kongresi, Antalya, Turkey, 16 - 21 November 2021, pp.204, (Full Text)

17. COMPARISON OF PROGNOSTIC SCORING SYSTEMS FOR PREDICTION OF SURVIVAL IN HEPATOCELLULAR CARCINOMA

Baran B., Ekinci O., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., et al.
EASL International Liver Congress, Barcelona, Spain, 13 - 17 April 2016, (Summary Text) Sustainable Development identifier identifier

18. Chronic Renal Failure after Liver Transplantation in Long Term: Prevalence and Risk Factors.

Gokturk S., Baran B., Ormeci A., Soyer O., Evirgen S., Ozden I., et al.
Joint International Congress of ILTS, ELITA and LICAGE, London, Canada, 4 - 07 June 2014, vol.20, (Summary Text) identifier

19. Evaluation of Small Bowel Mucosal Damage by Capsule Endoscopy in Familial Mediterranean Fever Patients

Demir A., Besisik F., Gokturk S., Evirgen S., Akyuz U., Ormeci A., et al.
55th Annual Meeting of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT) / Digestive Disease Week (DDW), Illinois, United States Of America, 3 - 06 May 2014, vol.146, (Summary Text) identifier

20. Is Diabetes Mellitus a Risk Factor for Gastroesophageal Reflux?

Gokturk S., Besisik F., Arici S., Alpaslan B., Ormeci A., Soyer O. M., et al.
55th Annual Meeting of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT) / Digestive Disease Week (DDW), Illinois, United States Of America, 3 - 06 May 2014, vol.146, (Summary Text) Sustainable Development identifier

21. ENTECAVIR AND TENOFOVIR HAVE A COMPARABLE EFFICACY IN TREATMENT OF NUCLEOS(T)IDE ANALOGUE NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A REAL LIFE EXPERIENCE

Baran B., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., Akyuz F., et al.
49th Annual International Liver Congress of the European-Association-for-the-Study-of-the-Liver, London, Canada, 9 - 13 April 2014, (Summary Text) identifier identifier

22. Baseline alfa-fetoprotein level is a strong predictor of vascular invasion and survival in patients with hepatocellular carcinoma

Ekinci O., Baran B., Ormeci A., Soyer O. M., Gokturk S., Poyanli A., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 November 2013, vol.58, (Summary Text) identifier

23. Risk factors for significant liver fibrosis in genotype D HBeAg-negative chronic hepatitis B infection with persistently normal ALT and high serum HBVDNA levels

Ormeci A., Akyuz F., Baran B., Soyer O. M., Gokturk S., Karaca C., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 November 2013, (Summary Text) Sustainable Development identifier

24. The antiviral efficacy of entecavir is not influenced by prior treatment with nucleos(t)ide analogues in patients with chronic hepatitis B

Baran B., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., Akyuz F., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 November 2013, (Summary Text) identifier

25. Tenofovir disoproxil fumarate has a substantial efficacy against adefovir and multi-drug resistant strains of hepatitis B virus

Baran B., Soyer O. M., Ormeci A., Gokturk S., Evirgen S., Akyuz F., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 November 2013, (Summary Text) Sustainable Development identifier

26. Virological Supression Does not Prevent the Development of Hepatocellular Carsinoma in Cirrhotic Patients with Genotype D Hepatitis B Infection

Gokturk S., Basar R., Ucar A. R., Basgoze B. H., Altinkaynak M., Buyukballi P., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 November 2013, vol.58, (Summary Text) Sustainable Development identifier

27. Safety of Tenofovir in Renal Transplanted and Hemodialysis Patients with Chronic Hepatitis B

Akyuz F., Gokturk S., Baran B., Ormeci A., Soyer O. M., Evirgen S., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 November 2013, vol.58, (Summary Text) Sustainable Development identifier

28. IL28B Polymorphisms and Influence on Sustained Virological Response to Interferon Therapy in Chronic DELTA Hepatitis

Karaca C., Yilmaz E., Soyer O. M., Onel D., ÖNEL M., Baran B., et al.
Digestive Disease Week / 28th Annual Residents and Fellows Research Conference of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT), Florida, United States Of America, 18 - 21 May 2013, vol.144, (Summary Text) Sustainable Development identifier

29. Does Chemoprophylaxis Prevent Tuberculosis Reactivation in the Long Term Period of Anti-TNF Treatment?

AKYÜZ F., Soyer O. M., Gokturk S., ÇİFCİBAŞI ÖRMECİ A., Evirgen S., Onder S. Y., et al.
Digestive Disease Week / 28th Annual Residents and Fellows Research Conference of the Society-for-Surgery-of-the-Alimentary-Tract (SSAT), Florida, United States Of America, 18 - 21 May 2013, vol.144, (Summary Text) identifier

30. TREATMENT FAILURE MAY LEAD TO ACCELERATED FIBROSIS PROGRESSION IN PATIENTS WITH CHRONIC HEPATITIS C

Baran B., Gulluoglu M., Soyer O., Ormeci A., Gokturk S., Evirgen S., et al.
International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Netherlands, 24 - 28 April 2013, (Summary Text) identifier identifier

31. Number connection test-A and inhibitor control test are not efficient for diagnosis of minimal hepatic encephalopathy in cirrhotic patients

Baran B., Ozcan E., Oztop N., Cakmak R., Soyer O. M., Ormeci A., et al.
63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 9 - 13 November 2012, vol.56, (Summary Text) identifier

32. Response to tenofovir treatment of treatment-naive and adefovir experienced patients with chronic hepatitis b

KESKİN O., Ormeci A., Kabacam G., Akyuz F., Aniktar H., Karaca C., et al.
63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 9 - 13 November 2012, vol.56, (Summary Text) Sustainable Development identifier

33. Success of Two Different Endoscopic Submucosal Resection Methods in Gastric Subepithelial Lesions

Karaca C., Soyer O. M., Akyuz F., Baran B., Ormeci A., Gokturk S., et al.
Digestive Disease Week (DDW), California, United States Of America, 19 - 22 May 2012, vol.75, pp.136, (Summary Text) identifier

34. RESPONSE TO TENOFOVIR TREATMENT OF TREATMENT-NAIVE VS ADEFOVIR-RESISTANT VS SUBOPTIMAL RESPONDER PATIENTS WITH CHRONIC HEPATITIS B

Keskin O., Ormeci A., Kabacam G., Akyuz F., Aniktar H., Karaca C., et al.
47th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Barcelona, Spain, 18 - 22 April 2012 identifier identifier
Metrics

Publication

96

Publication (WoS)

73

Publication (Scopus)

57

Citation (WoS)

384

H-Index (WoS)

12

Citation (Scopus)

416

H-Index (Scopus)

13

Citation (Scholar)

127

H-Index (Scholar)

4

Citation (TrDizin)

2

H-Index (TrDizin)

1

Citation (Sum Other)

2

Open Access

3
UN Sustainable Development Goals